Step I: FDA ARGOS Sample Submission Application

**Application Guidelines**

1. *The application should be submitted electronically per requirements via the [web site](https://argos.igs.umaryland.edu/).*
2. *There are no submission deadlines; applications can be submitted at anytime.*
3. *IGS and FDA personnel can [assist / guide](mailto:grc-info@som.umaryland.edu,%20FDA-ARGOS@fda.hhs.gov?subject=FDA%20ARGOS%20Sample%20Submission) you in preparing the application.*
4. *In the application, please respond to the following:*
   1. *State the relevance to infectious disease for the organism(s) to be studied; for example the public health significance, model system etc.*
   2. *Are there genome data for organisms in the same phylum / class / family / genus? What is the status of other sequencing / genotyping projects on the same organism? Provide information on other characteristics (genome size, GC content, repetitive DNA, pre- existing arrays etc.) relevant to the proposed study.*
   3. *Provide the rationale behind the selection of strains and the number of strains proposed in the study. Are the strains listed on the FDA ARGOS Preferred Organism List?*
   4. *For bacterial, fungal, and parasite organisms, are you able to provide >10ug of high-molecular weight genomic DNA for each isolate? For viral isolates, what genomic material will be provided?*
   5. *Can the resulting genome sequence data be promptly released to public archives (NCBI SRA, Genbank, etc.)?*
5. *Investigators can expect to receive a response within 4-6 weeks after submission.*

FDA ARGOS Sample Submission Application

Project Title:

Authors:

**Primary Investigator Contact:**

|  |  |
| --- | --- |
| Name |  |
| Position |  |
| Institution |  |
| Address |  |
| State |  |
| ZIP Code |  |
| Telephone |  |
| Fax |  |
| E-Mail |  |

1. Executive Summary

|  |
| --- |
|  |

2. Justification

|  |
| --- |
|  |

**3.** **Rationale for Strain Selection**

|  |
| --- |
|  |

4. Availability & Information of Strains:

|  |
| --- |
| 1. *Indicate availability of relevant laboratory strains and clinical isolates. Are the strains/isolates of interest retrospectively collected, prepared and ready to ship?* 2. *Attach relevant information, if available in an excel spreadsheet for multiple samples: e.g*   *• Name*  *• Identifier*  *• Material type (DNA/RNA/Strain)*  *• Genus*  *• Species*  *• Specimen / Strain*  *• Identification method*  *• Isolation source*  *• Isolated from/host*  *• Collected by*  *• Taxonomy\_ID*  *• Select agent status*  *• International permit requirement*  *• BEIR/ATCC repository accession number*  *• Other public repository location*  *• Other public repository identifier*  *• Sample provider’s name*  *• Sample provider’s contact*   1. *What supporting metadata and clinical data have been collected or are planned on being collected that could be made available for community use?* |

5. Public Data Release:

*Please confirm that resulting genome sequence data, genome assemblies & annotation, and related metadata will be promptly released to public archives, including but not limited to NCBI SRA and Genbank.*

Accept  Decline

5a. Public Data Access:

|  |
| --- |
| 1. *State any comments or concerns about rapid public genome data release.* |

Investigator Signature:

Investigator Name: Date